{"entity":{"id":"nct06480240","kind":"trial","name":"A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of OBI-992 in advanced solid tumours, run by OBI Pharma, Inc, active and no longer recruiting.","summary":"A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06480240 by OBI Pharma, Inc, with 117 participants enrolled, started 2024-06-12 and due to reach its primary completion in 2027-06. Interventions recorded: OBI-992.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06480240","url":"https://clinicaltrials.gov/study/NCT06480240"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06480240","phase":"1/2","setting":"A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-992 in Subjects With Advanced Solid Tumors","sponsor":"OBI Pharma, Inc","enrolled":117,"outcomes":[]},"route":"/trials/nct06480240/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"obi-992","kind":"drug","name":"OBI-992","route":"/drugs/obi-992/"}]}}